Filtered By:
Cancer: Lymphoma

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 25227 results found since Jan 2013.

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
CONCLUSIONS: To date, data on OS, quality of life, PFS, response rate, or short- and long-term AEs are available from small uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median OS was not reached after follow-up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint). Only one cohort out of three only reported quality of life, with limited follow-up data so that meaningful conclusions were not possible. Serious adverse events occurred rarely. C...
Source: Cochrane Database of Systematic Reviews - July 12, 2018 Category: General Medicine Authors: Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N Tags: Cochrane Database Syst Rev Source Type: research

Hodgkin Lymphoma in Adults.
CONCLUSION: The highly favorable long-term prognosis of HL necessitates careful consideration of the intensity of treatment as well as thorough follow-up to enable the detection of late sequelae, such as second tumors or organ damage. PMID: 30149835 [PubMed - in process]
Source: Deutsches Arzteblatt International - August 29, 2018 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research

Breast Implant-Associated Lymphoma.
CONCLUSION: The risk that a woman with breast implants will develop a primary anaplastic large-cell lymphoma is estimated at 0.35 to 1 case per million persons per year. The incidence of implant-associated ALCL is thus very low, yet nevertheless markedly higher than that of other primary lymphomas of the breast. Because of the low case numbers, recommendations for the diagnostic evaluation and treatment of this entity have not been adequately evaluated. Treatment with primary curative intent for BIA-ALCL confers a much better prognosis than when performed for a systemic ALCL. Whenever a patient with a breast implant presen...
Source: Deutsches Arzteblatt International - October 31, 2018 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research

Clinicopathological analysis of oral diffuse large B ‐cell lymphoma, NOS: a systematic review
ConclusionOral DLBCL NOS is an aggressive malignancy, but with a high survival rate.This article is protected by copyright. All rights reserved.
Source: Journal of Oral Pathology and Medicine - November 10, 2018 Category: Pathology Authors: Carla Isabelly Rodrigues ‐Fernandes, Lucas Lacerda de Souza, Sara Ferreira dos Santos‐Costa, Hélder Antônio Rebelo Pontes, Oslei Paes de Almeida, Pablo Agustin Vargas, Javier Rendón Henao, Siavash Rahimi, Peter A Brennan, Felipe Paiva Fons Tags: Invited Review Source Type: research

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316)
Conclusions. Applying an intention-to-treat analysis we did not demonstrate clinical benefit of sibling donor search and stem cell transplantation after a reduced intensity busulfan/fludarabine based regimen in AML patients ≥50 years in CR1. Early relapse was the main reason for preventing transplants in patients with an identified donor.Support from study groups: Canadian BMT Group, Australasian Leukaemia and Lymphoma Group, Norwegian/Swedish BMT Group, Swedish AML groupDisclosuresKiss: Alexion: Membership on an entity's Board of Directors or advisory committees, Research Funding; Otsuka: Membership on an entity's Boar...
Source: Blood - November 21, 2018 Category: Hematology Authors: Brune, M., Kiss, T. L., Wallhult, E., Anderson, H., Delage, R., Finke, J., Hebert, J., Hoglund, M., Kaare, A., Lazarevic, V., Nicklasson, M., Remes, K., Ritchie, D., Sabloff, M., Spearing, R., Spyridonidis, A., Szer, J., Ljungman, P. Tags: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question Source Type: research

Genome Wide Association Analyses Identify Pleiotropic Variants Associated with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Susceptibility
The first two authors and last two authors contributed equally.Genome-wide association studies (GWAS) have identified risk loci for Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL) and Non-Hodgkin Lymphoma, however an Acute Myeloid Leukemia (AML) GWAS has not been published to date. We performed a GWAS to identify AML and Myelodysplastic Syndrome (MDS) risk loci using a nested case-control study design in the DISCOVeRY-BMT cohorts which includes almost 2000 AML and MDS patients as cases and 2813 unrelated donors as controls.Genotyping was performed using the Illumina Human OmniExpress BeadChip and i...
Source: Blood - November 21, 2018 Category: Hematology Authors: Wang, J., Clay-Gilmour, A. I., Karaesmen, E., Rizvi, A., Zhu, Q., Yan, L., Preus, L., Liu, S., Stram, D., Pooler, L., Cheng, X., Haiman, C., Van Den Berg, D., Webb, A., Brock, G., Griffiths, E. A., Spellman, S. R., Pasquini, M. C., McCarthy, P. L., Allan, Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Source Type: research

Risk of Atrial Fibrillation with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials
Conclusion: In agreement with prior reports, this updated meta-analysis confirmed that ibrutinib was associated with a significantly increased risk of all grade AF in pts with B-cell malignancies (RR 4.27). Our analysis shows that the risk of high grade AF (grade3-5) is also significantly increased with ibrutinib (RR 4.85). These pts need to be closely monitored for development of AF to help improve morbidity and mortality.DisclosuresShort: Takeda Oncology: Consultancy. Maiti: Celgene Corporation: Other: Research funding to the institution.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ball, S., Vutthikraivit, W., Das, A., Edwards, P. J., Tijani, L., Short, N. J., Maiti, A. Tags: 642. CLL: Therapy, excluding Transplantation: Poster I Source Type: research

Risk of Infection with Ibrutinib in Patients with B-Cell Malignancies: A Meta-Analysis of Phase III Randomized Controlled Trials
Conclusion: In this meta-analysis, ibrutinib was associated with significantly increased risk of infection in pts with B-cell malignancies, whereas this risk was not significantly increased when the analysis was limited to patients with CLL. Future well-designed prospective trials with longer duration of follow up are needed to truly evaluate the association of ibrutinib and infections in pts with B-cell malignancies.DisclosuresShort: Takeda Oncology: Consultancy. Maiti: Celgene Corporation: Other: Research funding to the institution.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ball, S., Vutthikraivit, W., Das, A., Edwards, P. J., Hardwicke, F., Short, N. J., Maiti, A. Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster II Source Type: research

Classical Hodgkin Lymphoma Patients Have an Increased Incidence of Idiopathic Acquired Aplastic Anemia
In conclusion, the data suggest that patients with HL have a significantly higher incidence of AA compared to the general population. The underlying reason for this association is not known; however, the development of AA after HL, a unique B-cell neoplasm associated with a marked inflammatory component, without having received prior cytotoxic therapy in half of the cases, points to secondary immune dysregulation as the possible etiologic factor for AA pathogenesis. Recognition of this syndrome and improved management algorithms are needed for the management of AA presenting in patients with HL.DisclosuresFrey: Novartis: C...
Source: Blood - November 21, 2018 Category: Hematology Authors: Linaburg, T., Davis, A. R., Frey, N. V., Landsburg, D. J., Schuster, S. J., Svoboda, J., Li, Y., Borovskiy, Y., Olson, T. S., Bagg, A., Hexner, E. O., Babushok, D. V. Tags: 508. Bone Marrow Failure Source Type: research

Clinical Response and Tolerability of Selinexor in Acute Myeloid Leukemia and Other Hematologic Malignancies - a Systematic Review
Conclusion:Selinexor based combination regimens have shown better clinical response against AML as compared to monotherapy. The efficacy results in multiple myeloma and other hematological malignancies are also encouraging. The adverse events like cytopenias were common as in other chemotherapy regimens.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Tariq, M. J., Yasir, M., Khalid, A., Amin, S. N., Samuel, S., Khalil, M. J., Aslam, S., Ahmad, M. Q., Fraz, M. A., Usman, M., Ijaz, A., Farooqui, A. A., Durer, S., Durer, C., Anwer, F. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Source Type: research

Risk of Bleeding with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials
Conclusion: In this meta-analysis, ibrutinib was associated with a significantly increased risk of overall bleeding in patients with B-cell malignancies, and incidence of major hemorrhages in ibrutinib arm showed trend towards statistical significance. Knowledge about increased risk of this adverse event should help clinicians to contribute to alleviation of overall morbidity and mortality in patients.DisclosuresMaiti: Celgene Corporation: Other: Research funding to the institution.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ball, S., Maiti, A., Arevalo, M., Das, A., Vutthikraivit, W., Edwards, P. J., Hardwicke, F. Tags: 642. CLL: Therapy, excluding Transplantation Source Type: research

A Systematic Literature Review of Real-World Evidence in Post-Transplant Lymphoproliferative Disorder
Conclusions: To the best of our knowledge, this is the first comprehensive SLR to examine the published real-world evidence in patients with PTLD. Our SLR reveals important differences with respect to methodology and reporting of real-world published studies assessing the current landscape in PTLD. Additional large, high-quality studies employing more rigorous study methodology are required to understand the current landscape of PTLD in the real-world setting.DisclosuresXu: Atara Biotherapeutics, Inc: Employment, Equity Ownership. Forsythe: Novartis: Consultancy. Barlev: Atara Biotherapeutics, Inc: Employment, Equity Owner...
Source: Blood - November 21, 2018 Category: Hematology Authors: Xu, H., Forsythe, A., Barlev, A., Rashid, N., Watson, C. Tags: 902. Health Services Research-Malignant Diseases Source Type: research

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies
CONCLUSIONS: We found that the treatment-related cost burden of rituximab in malignant conditions is substantial, while its associated toxicity is relatively low, and patient QOL is maintained or improved. Incident and increased toxicities associated with rituximab added to CT may or may not be exclusively attributable to rituximab. Administration rate and route influence economic endpoints with rituximab use. These findings highlight the potential economic benefit of lower-cost biosimilar rituximab products for patients, health care systems, and payers.[1] This Abstract is not intended to refer to any particular biosimila...
Source: Blood - November 21, 2018 Category: Hematology Authors: James, E., Trautman, H., Hoehn, G., Szabo, E., Tang, B. Tags: 904. Outcomes Research-Malignant Conditions Source Type: research

Fine-needle aspiration to diagnose primary thyroid lymphoma: a systematic review and meta-analysis.
CONCLUSIONS: The present meta-analysis demonstrated that FNA has low sensitivity in diagnosing PTL. However, this rate increased when considering also FNA reports suspicious for PTL, which is relevant from a clinical standpoint. This result could support indirectly the use of additional imaging and/or core biopsy when PTL is suspected. PMID: 30566902 [PubMed - as supplied by publisher]
Source: European Journal of Endocrinology - December 1, 2018 Category: Endocrinology Authors: Zhang L, Castellana M, Virili C, Crescenzi A, Giorgino F, Zucca E, Ceriani L, Cavalli F, Giovanella L, Trimboli P Tags: Eur J Endocrinol Source Type: research

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research